Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other research firms have also recently issued reports on EGRX. Zacks Investment Research cut shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Royal Bank Of Canada set a $86.00 price objective on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, April 24th. Piper Jaffray Companies set a $118.00 price objective on shares of Eagle Pharmaceuticals and gave the stock an “overweight” rating in a research report on Tuesday, May 9th. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 16th. Finally, Mizuho lowered their price objective on shares of Eagle Pharmaceuticals from $66.00 to $57.00 and set an “underperform” rating for the company in a research report on Thursday, May 25th. Three investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $75.40.

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) opened at 55.64 on Friday. The stock’s 50 day moving average is $67.41 and its 200 day moving average is $76.03. The firm has a market cap of $844.00 million, a price-to-earnings ratio of 9.34 and a beta of 1.31. Eagle Pharmaceuticals has a 12-month low of $45.05 and a 12-month high of $97.15.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.51 by $0.18. The firm had revenue of $50.10 million for the quarter, compared to the consensus estimate of $52.52 million. Eagle Pharmaceuticals had a return on equity of 66.30% and a net margin of 39.32%. The business’s revenue was up 22.5% on a year-over-year basis. During the same period last year, the company posted $0.80 EPS. Equities analysts expect that Eagle Pharmaceuticals will post $3.38 earnings per share for the current year.

Eagle Pharmaceuticals declared that its board has initiated a share buyback program on Wednesday, August 9th that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the specialty pharmaceutical company to repurchase up to 13.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

TRADEMARK VIOLATION NOTICE: “Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Stock Rating Upgraded by BidaskClub” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/12/eagle-pharmaceuticals-inc-nasdaqegrx-stock-rating-upgraded-by-bidaskclub.html.

In other Eagle Pharmaceuticals news, Director Douglas L. Braunstein purchased 20,400 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was purchased at an average cost of $49.07 per share, for a total transaction of $1,001,028.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Pete A. Meyers purchased 350 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was acquired at an average price of $71.49 per share, with a total value of $25,021.50. Following the completion of the transaction, the chief financial officer now owns 350 shares in the company, valued at approximately $25,021.50. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 21,205 shares of company stock valued at $1,062,818. 19.50% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue boosted its position in shares of Eagle Pharmaceuticals by 78.9% in the second quarter. State of Alaska Department of Revenue now owns 1,592 shares of the specialty pharmaceutical company’s stock valued at $125,000 after buying an additional 702 shares during the period. BNP Paribas Arbitrage SA boosted its position in shares of Eagle Pharmaceuticals by 15.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,548 shares of the specialty pharmaceutical company’s stock valued at $128,000 after buying an additional 202 shares during the period. Municipal Employees Retirement System of Michigan boosted its position in shares of Eagle Pharmaceuticals by 6.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 120 shares during the period. Mason Street Advisors LLC boosted its position in shares of Eagle Pharmaceuticals by 10.2% in the first quarter. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company’s stock valued at $157,000 after buying an additional 175 shares during the period. Finally, Bank of Montreal Can boosted its position in shares of Eagle Pharmaceuticals by 323.9% in the second quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 1,908 shares during the period.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.